100 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
10
Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.
Pfizer
2
Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists.
Ruhr University of Bochum
2
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
The University of Arizona
33
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
2
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy.
Shengjing Hospital of China Medical University
3
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC.
Risen (Shanghai) Pharma Tech Co., Ltd.
21
Identification of Structurally Novel KRASG12C Inhibitors through Covalent DNA-Encoded Library Screening.
Amgen
35
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
CRUK Scotland Institute
1
Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer.
Nanjing Tech University
27
Peptide inhibitors targeting Ras and Ras-associated protein-protein interactions.
Second Military Medical University
24
Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C.
Jacobio Pharmaceuticals Group Co., Ltd.
18
Size-Dependent Target Engagement of Covalent Probes.
HUN-REN Research Centre for Natural Sciences
15
Innovative design and potential applications of covalent strategy in drug discovery.
Sichuan University
11
Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery.
Monash University (Malaysia Campus)
14
Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.
Iowa State University
12
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
University of Petroleum and Energy Studies
14
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor.
Merck & Co.
37
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Bayer AG
14
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.
Tianjin University of Science & Technology
19
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.
Children's Hospital Affiliated to Zhengzhou University
7
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors.
Usona Institute
22
An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth.
University of Luxembourg
13
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display.
Chugai Pharmaceutical Co. Ltd.
2
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D.
Shanghai Institute of Materia Medica
7
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
Jiangxi Science & Technology Normal University
43
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Eberhard Karls University Tubingen
48
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery.
Sichuan University
5
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
Shanghai Jiao Tong University
18
Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects.
Sun Yat-Sen University
13
Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors.
Erasca
26
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS
AstraZeneca
34
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
China Pharmaceutical University
15
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS
Novartis Institutes For Biomedical Research
13
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
Boehringer Ingelheim Rcv
11
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
AstraZeneca
1
Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
Southern Medical University
20
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Massachusetts College of Pharmacy and Health Sciences University
6
Drugging the Next Undruggable KRAS Allele-Gly12Asp.
University of California San Francisco
45
Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology.
Merck
11
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics.
Usona Institute
8
Cyclic Peptide Screening Methods for Preclinical Drug Discovery.
University of Washington
1
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Sun Yat-Sen University
18
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Astellas Pharma
82
Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.
Cambridge University
29
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Mirati Therapeutics
9
A Series of Pyrazole Analogs Binding to KRASG12C as Potential Cancer Treatment.
Arrival Discovery
12
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer.
Usona Institute
8
Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer.
Usona Institute
11
Dual Inhibition of KRAS G12C and G12D Mutants as a Potential Treatment in Cancer Therapy.
Usona Institute
11
Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer.
Usona Institute
6
Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
Shanghai Institute of Materia Medica (Simm)
2
De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits.
Msd
2
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.
Lilly Research Laboratories
6
Fragment-to-Lead Medicinal Chemistry Publications in 2019.
Novartis Institutes For Biomedical Research
34
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
TBA
12
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Jinan University
10
Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Wright State University
17
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
AstraZeneca
5
Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
China Pharmaceutical University
6
Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.
Therachem Research Medilab
10
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Array Biopharma
5
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
University of Houston
18
Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications.
Shengjing Hospital of China Medical University
1
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.
Pfizer
1
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Takeda Pharmaceutical
17
Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.
Takeda Pharmaceutical
19
Benzothiophene derivative regulator, preparation method therefor and use thereof
Shanghai Hansoh Biomedical
146
ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO
Arena Pharmaceuticals
46
COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF
Medifron Dbt
59
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
The Usa, As Represented By The Secretary, Dhhs